BI
BVF Inc Portfolio holdings
AUM
$2.8B
This Quarter Return
+26.47%
1 Year Return
+17.96%
3 Year Return
+404.14%
5 Year Return
+563.41%
10 Year Return
+5,885.83%
AUM
$2.37B
AUM Growth
+$2.37B
(-2.1%)
Cap. Flow
-$70.6M
Cap. Flow
% of AUM
-2.98%
Top 10 Holdings %
Top 10 Hldgs %
45.23%
Holding
88
New
8
Increased
6
Reduced
18
Closed
10
Top Buys
| 1 |
Axsome Therapeutics
AXSM
|
$135M |
| 2 |
Zymeworks
ZYME
|
$46.1M |
| 3 |
Immunovant
IMVT
|
$45.5M |
| 4 |
PNT
POINT Biopharma Global Inc. Common Stock
PNT
|
$26.2M |
| 5 |
Replimune Group
REPL
|
$16.2M |
Top Sells
| 1 |
Relmada Therapeutics
RLMD
|
$76.9M |
| 2 |
Ionis Pharmaceuticals
IONS
|
$66.1M |
| 3 |
CINC
CinCor Pharma, Inc. Common Stock
CINC
|
$43.1M |
| 4 |
Nuvalent
NUVL
|
$32.4M |
| 5 |
EQRX
EQRx, Inc. Common Stock
EQRX
|
$29.7M |
Sector Composition
| 1 | Healthcare | 99.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
MoonLake Immunotherapeutics
MLTX
$3.54B
| $228M | 9.64% | 21,751,284 | – | – |
|
|
2
Axsome Therapeutics
AXSM
$6.05B
| $135M | 5.71% | +1,755,000 | New | +$135M |
|
3
Repare Therapeutics
RPTX
$71.7M
| $122M | 5.15% | 8,291,988 | – | – |
|
4
Kymera Therapeutics
KYMR
$2.95B
| $117M | 4.94% | 4,692,604 | – | – |
|
5
GH Research
GHRS
$837M
| $89.7M | 3.79% | 9,275,158 | – | – |
|
6
4D Molecular Therapeutics
FDMT
$288M
| $89M | 3.76% | 4,007,413 | – | – |
|
7
Cullinan Oncology
CGEM
$445M
| $79.2M | 3.34% | 7,509,059 | – | – |
|
8
Revolution Medicines
RVMD
$7.1B
| $77.5M | 3.27% | 3,255,588 | – | – |
|
|
PNT
9
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $66.9M | 2.82% | 9,177,748 +3,587,700 | +64% | +$26.2M |
|
10
Xoma
XOMA
$392M
| $66.5M | 2.8% | 3,611,494 | – | – |
|
11
Relay Therapeutics
RLAY
$619M
| $57.9M | 2.44% | 3,876,021 -463,500 | -11% | -$6.92M |
|
|
CTIC
12
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $53M | 2.24% | 8,813,021 | – | – |
|
13
Aclaris Therapeutics
ACRS
$209M
| $51.6M | 2.18% | 3,276,543 -700,000 | -18% | -$11M |
|
14
Xenon Pharmaceuticals
XENE
$2.98B
| $50.1M | 2.12% | 1,271,243 +370,148 | +41% | +$14.6M |
|
15
Crinetics Pharmaceuticals
CRNX
$2.92B
| $50.1M | 2.11% | 2,736,613 -942,334 | -26% | -$17.2M |
|
16
Arcus Biosciences
RCUS
$1.13B
| $47.6M | 2.01% | 2,303,520 -413,500 | -15% | -$8.55M |
|
17
Kura Oncology
KURA
$686M
| $47.2M | 1.99% | 3,800,983 +597,200 | +19% | +$7.41M |
|
|
18
Zymeworks
ZYME
$1.12B
| $46.1M | 1.95% | +5,870,000 | New | +$46.1M |
|
19
Merus
MRUS
$4.98B
| $46.1M | 1.94% | 2,978,420 -466,000 | -14% | -$7.21M |
|
|
20
Immunovant
IMVT
$2.56B
| $45.5M | 1.92% | +2,561,000 | New | +$45.5M |
|
|
21
Ionis Pharmaceuticals
IONS
$6.79B
| $42.4M | 1.79% | 1,121,809 -1,751,144 | -61% | -$66.1M |
|
|
ALLK
22
DELISTED
Allakos
ALLK
| $42.2M | 1.78% | 5,006,921 | – | – |
|
|
23
Replimune Group
REPL
$422M
| $41.4M | 1.75% | 1,522,629 +596,100 | +64% | +$16.2M |
|
24
IDEAYA Biosciences
IDYA
$2.15B
| $40.1M | 1.69% | 2,205,089 -1,089,770 | -33% | -$19.8M |
|
25
Syndax Pharmaceuticals
SNDX
$1.41B
| $36.9M | 1.56% | 1,451,197 -346,888 | -19% | -$8.83M |
|